Patrick B. Mazi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patrick B. Mazi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Andrej Spec
Division of Infectious Diseases, Department of Medicine, Washington University in St Louis School of Medicine , St Louis, Missouri
7 shared publications - Adriana M. Rauseo
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, USA
4 shared publications - Julio Cesar Zuniga-Moya
Division of Infectious Diseases, Department of Medicine, Washington University in St Louis School of Medicine , St Louis, Missouri
4 shared publications William G Powderly
Division of Infectious Diseases, Department of Medicine, Washington University in St Louis School of Medicine , St Louis, Missouri
3 shared publicationsAdriana M Rauseo
Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine , St Louis, Missouri , USA
2 shared publicationsAndrej Spec
Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, USA
2 shared publications
Latest Publications
- 6 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Histoplasma capsulatum Antigen Persistence and Rate of Decay During Treatment of Histoplasmosis Varies by Immune Status
Background: Previous studies examining Histoplasma antigen trends are largely in people with human immunodeficiency virus (PWH) before the antiretroviral therapy era, with limited generalizability to modern cohorts of histoplasmosis. Methods: We conducted a single-center, retrospective study of adult patients diagnosed with histoplasmosis by positive antigen testing and undergoing treatment between 2007 and 2021. Mean rates of antigen clearance (in log10 ng/mL) were estimated using a linear mixed-effects model. Time to H capsulatum antigen negativity was calculated using competing risk analysis. Per-patient, mean antigen levels were compared at time of diagnosis and subsequent 6-month intervals. Results: A total of 83 patients met the inclusion criteria: 25 transplant, 21 immunocompetent, 16 biologic therapy, 11 PWH, and 10 with other immunocompromise (OI). The transplant (−0.07), biologic (−0.07), and OI (−0.05) groups cleared antigenuria significantly slower than PWH (−0.21) and the immunocompetent group (−0.16). Median time to antigen negativity in the presence of competing risk of death was as follows: transplant, 20.3 (95% CI: 11.6–69.3) months; biologic, 14.6 (9.0–42.6) months; OI, 13.2 (2.0–82.5) months; PWH, 12.9 (1.9–19.2) months; and immunocompetent, 6.8 (2.8–13.0) months. At 1 year, antigen positivity was more common in immunocompromised than immunocompetent patients (22/40 [55%] vs 3/16 [19%]; P = .02) and among the immunocompromised groups only transplant, biologic, and OI patients had positivity at 2 years. Conclusions: Patients with chronic non-HIV immunosuppression demonstrated persistent antigenuria and cleared antigen more slowly compared with immunocompetent patients and immune-reconstituted PWH. Given the association of antigen persistence with immune status, its clinical significance in non–HIV-immunocompromised populations requires evaluation.
- 6 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Histoplasma capsulatum Antigen Persistence and Rate of Decay During Treatment of Histoplasmosis Varies by Immune Status
Background: Previous studies examining Histoplasma antigen trends are largely in people with human immunodeficiency virus (PWH) before the antiretroviral therapy era, with limited generalizability to modern cohorts of histoplasmosis. Methods: We conducted a single-center, retrospective study of adult patients diagnosed with histoplasmosis by positive antigen testing and undergoing treatment between 2007 and 2021. Mean rates of antigen clearance (in log10 ng/mL) were estimated using a linear mixed-effects model. Time to H capsulatum antigen negativity was calculated using competing risk analysis. Per-patient, mean antigen levels were compared at time of diagnosis and subsequent 6-month intervals. Results: A total of 83 patients met the inclusion criteria: 25 transplant, 21 immunocompetent, 16 biologic therapy, 11 PWH, and 10 with other immunocompromise (OI). The transplant (−0.07), biologic (−0.07), and OI (−0.05) groups cleared antigenuria significantly slower than PWH (−0.21) and the immunocompetent group (−0.16). Median time to antigen negativity in the presence of competing risk of death was as follows: transplant, 20.3 (95% CI: 11.6–69.3) months; biologic, 14.6 (9.0–42.6) months; OI, 13.2 (2.0–82.5) months; PWH, 12.9 (1.9–19.2) months; and immunocompetent, 6.8 (2.8–13.0) months. At 1 year, antigen positivity was more common in immunocompromised than immunocompetent patients (22/40 [55%] vs 3/16 [19%]; P = .02) and among the immunocompromised groups only transplant, biologic, and OI patients had positivity at 2 years. Conclusions: Patients with chronic non-HIV immunosuppression demonstrated persistent antigenuria and cleared antigen more slowly compared with immunocompetent patients and immune-reconstituted PWH. Given the association of antigen persistence with immune status, its clinical significance in non–HIV-immunocompromised populations requires evaluation.
- Open Access
- 19 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
A Call to Investigate the Association Between Histoplasmosis and Fatigue
Historically, infections are subjectively associated with fatigue, a common yet poorly delineated syndrome. The impact on patient quality of life is the ultimate justification to evaluate fatigue in patients with infections. While fungal infections are subjectively associated with fatigue, there are minimal quantifiable fungal research outcomes that evaluate histoplasmosis and fatigue.
- 19 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Open AccessA Call to Investigate the Association Between Histoplasmosis and Fatigue
Historically, infections are subjectively associated with fatigue, a common yet poorly delineated syndrome. The impact on patient quality of life is the ultimate justification to evaluate fatigue in patients with infections. While fungal infections are subjectively associated with fatigue, there are minimal quantifiable fungal research outcomes that evaluate histoplasmosis and fatigue.
- Open Access
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10) , ofae755
Mapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database
Background: The dimorphic mycoses (DMs) histoplasmosis, blastomycosis, and coccidioidomycosis are classically thought to be geographically restricted to specific regions of the United States. The current scientific consensus is that these geographic boundaries are expanding, but the extent of this expansion remains uncertain. Methods: This study is a retrospective analysis of >21 million (annually) commercially insured individuals within the United States during 2007–2016. Diagnosis of histoplasmosis, coccidioidomycosis, and blastomycosis were identified using International Classification of Diseases, Ninth/Tenth Revision codes within the Merative MarketScan database. Results: There were 37 513 histoplasmosis, 14 987 coccidioidomycosis, and 2207 blastomycosis diagnoses during 2007–2016 within 387 Metropolitan Statistical Areas. DMs were consistently diagnosed outside their historical hyperendemic regions. Conclusions: New diagnoses of histoplasmosis, coccidioidomycosis, and blastomycosis were routinely made outside their historically defined regions of endemicity. While exposure to hyperendemic regions remains a risk factor for developing a DM infection, clinicians should consider testing any patient presenting with a compatible clinical syndrome, regardless of their geographic history. Increased suspicion of DM infection will lead to fewer missed or delayed diagnoses, thereby improving patient outcomes.
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10) , ofae755
Open AccessMapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database
Background: The dimorphic mycoses (DMs) histoplasmosis, blastomycosis, and coccidioidomycosis are classically thought to be geographically restricted to specific regions of the United States. The current scientific consensus is that these geographic boundaries are expanding, but the extent of this expansion remains uncertain. Methods: This study is a retrospective analysis of >21 million (annually) commercially insured individuals within the United States during 2007–2016. Diagnosis of histoplasmosis, coccidioidomycosis, and blastomycosis were identified using International Classification of Diseases, Ninth/Tenth Revision codes within the Merative MarketScan database. Results: There were 37 513 histoplasmosis, 14 987 coccidioidomycosis, and 2207 blastomycosis diagnoses during 2007–2016 within 387 Metropolitan Statistical Areas. DMs were consistently diagnosed outside their historical hyperendemic regions. Conclusions: New diagnoses of histoplasmosis, coccidioidomycosis, and blastomycosis were routinely made outside their historically defined regions of endemicity. While exposure to hyperendemic regions remains a risk factor for developing a DM infection, clinicians should consider testing any patient presenting with a compatible clinical syndrome, regardless of their geographic history. Increased suspicion of DM infection will lead to fewer missed or delayed diagnoses, thereby improving patient outcomes.
- Open Access
- 5 August 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106568
Geographic distribution and associated mortality of invasive aspergillosis and mucormycosis among Medicare enrollees in the United States (2008-2015)
- 5 August 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106568
Open AccessGeographic distribution and associated mortality of invasive aspergillosis and mucormycosis among Medicare enrollees in the United States (2008-2015)
- Open Access
- 26 April 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae226
Shared Vision for Improving Outcomes for Serious Fungal Diseases: Report of a Patient, Caregiver, and Clinician Summit
Background: Recently, increasing focus on patient input into research and healthcare improvements has fostered expanded patient-centered advocacy efforts. This first pan-fungal disease summit, part of the MYCology Advocacy, Research, & Education effort, brought together patients, caregivers, and mycology experts to better document patient experiences with invasive fungal disease (IFD) and establish priorities for mycology education, advocacy, and research. Methods: Patients who had suffered from IFD, their caregivers, clinicians, industry representatives, government officials, and patient advocacy professionals were invited. Patients and caregivers shared their stories and struggles with IFD. Breakout sessions separated mycology experts from patients and caregivers for further discussions to identify commonalities and perceived gaps and to formulate recommendations. The 2 groups then reconvened to develop consensus recommendations. Results: IFD patients and their caregivers shared experiences reflecting the typically lengthy prediagnosis, acute treatment, long-term treatment, and posttreatment recovery stages of IFD. They reported substantial physical, psychological, and financial burdens associated with the IFD experience, particularly related to delayed diagnoses. They reaffirmed a need for coordinated patient-centered education, peer support, and advocacy to document the burden of serious fungal infections. Mycology experts discussed strategies to address gaps in the mycology field, such as insufficient training, inadequate workforce support, and a need to partner more with patient groups. Conclusions: A summit involving patients with IFD, family caregivers, and mycology experts identified a substantial nonclinical burden of disease associated with IFD. Patients and mycology experts prioritized several goals for education, advocacy, and research to raise awareness of IFD and improve outcomes.
- 26 April 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae226
Open AccessShared Vision for Improving Outcomes for Serious Fungal Diseases: Report of a Patient, Caregiver, and Clinician Summit
Background: Recently, increasing focus on patient input into research and healthcare improvements has fostered expanded patient-centered advocacy efforts. This first pan-fungal disease summit, part of the MYCology Advocacy, Research, & Education effort, brought together patients, caregivers, and mycology experts to better document patient experiences with invasive fungal disease (IFD) and establish priorities for mycology education, advocacy, and research. Methods: Patients who had suffered from IFD, their caregivers, clinicians, industry representatives, government officials, and patient advocacy professionals were invited. Patients and caregivers shared their stories and struggles with IFD. Breakout sessions separated mycology experts from patients and caregivers for further discussions to identify commonalities and perceived gaps and to formulate recommendations. The 2 groups then reconvened to develop consensus recommendations. Results: IFD patients and their caregivers shared experiences reflecting the typically lengthy prediagnosis, acute treatment, long-term treatment, and posttreatment recovery stages of IFD. They reported substantial physical, psychological, and financial burdens associated with the IFD experience, particularly related to delayed diagnoses. They reaffirmed a need for coordinated patient-centered education, peer support, and advocacy to document the burden of serious fungal infections. Mycology experts discussed strategies to address gaps in the mycology field, such as insufficient training, inadequate workforce support, and a need to partner more with patient groups. Conclusions: A summit involving patients with IFD, family caregivers, and mycology experts identified a substantial nonclinical burden of disease associated with IFD. Patients and mycology experts prioritized several goals for education, advocacy, and research to raise awareness of IFD and improve outcomes.
- 27 March 2023
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 17 (2) , 124-131
Management of HIV-Associated Cryptococcal Meningitis
- 27 March 2023
- Published by Springer Nature in Current Fungal Infection Reports
- Vol. 17 (2) , 124-131
Management of HIV-Associated Cryptococcal Meningitis
- Top Cited Papers
- 11 November 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (7) , 1295-1301
The Geographic Distribution of Dimorphic Mycoses in the United States for the Modern Era
The dimorphic mycoses (DMs) of the United States—Histoplasma, Coccidioides, and Blastomyces—commonly known as endemic mycoses of North America (in addition to Paracoccidioides) are increasingly being diagnosed outside their historical areas of endemicity. Despite this trend, the maps outlining their geographic distributions have not been updated in more than half a century using a large, nationwide database containing individual-patient–level data. This was a retrospective analysis of >45 million Medicare fee-for-service beneficiaries from 1 January 2007 through 31 December 2016. Diagnoses of histoplasmosis, coccidioidomycosis, and blastomycosis were defined by International Classification of Diseases, Ninth/10th Revision, codes. The primary outcome was the incidence of histoplasmosis, coccidioidomycosis, and blastomycosis for each US county. Clinically meaningful thresholds for incidence were defined as 100 cases/100 000 person-years for histoplasmosis and coccidioidomycosis and 50 cases/100 000 person-years for blastomycosis. There were 79 749 histoplasmosis, 37 726 coccidioidomycosis, and 6109 blastomycosis diagnoses in unique persons from 2007–2016 across 3143 US counties. Considering all US states plus Washington, DC, 94% (48/51) had ≥1 county above the clinically relevant threshold for histoplasmosis, 69% (35/51) for coccidioidomycosis, and 78% (40/51) for blastomycosis. Persons with histoplasmosis, coccidioidomycosis, and blastomycosis are diagnosed in significant numbers outside their historical geographic distributions established >50 years ago. Clinicians should consider DM diagnoses based on compatible clinical syndromes with less emphasis placed on patients' geographic exposure. Increased clinical suspicion leading to a subsequent increase in DM diagnostic testing would likely result in fewer missed diagnoses, fewer diagnostic delays, and improved patient outcomes.
- 11 November 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (7) , 1295-1301
Top Cited PapersThe Geographic Distribution of Dimorphic Mycoses in the United States for the Modern Era
The dimorphic mycoses (DMs) of the United States—Histoplasma, Coccidioides, and Blastomyces—commonly known as endemic mycoses of North America (in addition to Paracoccidioides) are increasingly being diagnosed outside their historical areas of endemicity. Despite this trend, the maps outlining their geographic distributions have not been updated in more than half a century using a large, nationwide database containing individual-patient–level data. This was a retrospective analysis of >45 million Medicare fee-for-service beneficiaries from 1 January 2007 through 31 December 2016. Diagnoses of histoplasmosis, coccidioidomycosis, and blastomycosis were defined by International Classification of Diseases, Ninth/10th Revision, codes. The primary outcome was the incidence of histoplasmosis, coccidioidomycosis, and blastomycosis for each US county. Clinically meaningful thresholds for incidence were defined as 100 cases/100 000 person-years for histoplasmosis and coccidioidomycosis and 50 cases/100 000 person-years for blastomycosis. There were 79 749 histoplasmosis, 37 726 coccidioidomycosis, and 6109 blastomycosis diagnoses in unique persons from 2007–2016 across 3143 US counties. Considering all US states plus Washington, DC, 94% (48/51) had ≥1 county above the clinically relevant threshold for histoplasmosis, 69% (35/51) for coccidioidomycosis, and 78% (40/51) for blastomycosis. Persons with histoplasmosis, coccidioidomycosis, and blastomycosis are diagnosed in significant numbers outside their historical geographic distributions established >50 years ago. Clinicians should consider DM diagnoses based on compatible clinical syndromes with less emphasis placed on patients' geographic exposure. Increased clinical suspicion leading to a subsequent increase in DM diagnostic testing would likely result in fewer missed diagnoses, fewer diagnostic delays, and improved patient outcomes.
- 5 January 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 75 (6) , 1031-1036
Attributable Mortality of Candida Bloodstream Infections in the Modern Era: A Propensity Score Analysis
This study quantifies the mortality attributable to Candida bloodstream infections (BSI) in the modern era of echinocandins. We conducted a retrospective cohort study of adult patients admitted to Barnes Jewish Hospital, a 1368-bed tertiary care academic hospital, in Saint Louis, Missouri, from 1 February 2012 to 30 April 2019. We identified 626 adult patients with Candida BSI that were frequency-matched with 6269 control patients that had similar Candida BSI risk-factors. The 90-day all-cause mortality attributable to Candida BSI was calculated using three methods—propensity score matching, matching by inverse weighting of propensity score, and stratified analysis by quintile. The 90-day crude mortality was 42.4% (269 patients) for Candida BSI cases and 17.1% (1083 patients) for frequency-matched controls. Following propensity score-matching, the attributable risk difference for 90-day mortality was 28.4% with hazard ratio (HR) of 2.12 (95% confidence interval [CI], 1.98–2.25, P < .001). In the stratified analysis, the risk for mortality at 90 days was highest in patients in the lowest risk quintile to develop Candida BSI (hazard ratio [HR] 3.13 (95% CI, 2.33–4.19). Patients in this lowest risk quintile accounted for 81(61%) of the 130 untreated patients with Candida BSI. Sixty-nine percent of untreated patients (57/83) died versus 35% of (49/127) of treated patients (P < .001). Patients with Candida BSI continue to experience high mortality. Mortality attributable to Candida BSI was more pronounced in patients at lowest risk to develop Candida BSI. A higher proportion of these low-risk patients went untreated, experienced higher mortality, and should be the target of aggressive interventions to ensure timely, effective treatment.
- 5 January 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 75 (6) , 1031-1036
Attributable Mortality of Candida Bloodstream Infections in the Modern Era: A Propensity Score Analysis
This study quantifies the mortality attributable to Candida bloodstream infections (BSI) in the modern era of echinocandins. We conducted a retrospective cohort study of adult patients admitted to Barnes Jewish Hospital, a 1368-bed tertiary care academic hospital, in Saint Louis, Missouri, from 1 February 2012 to 30 April 2019. We identified 626 adult patients with Candida BSI that were frequency-matched with 6269 control patients that had similar Candida BSI risk-factors. The 90-day all-cause mortality attributable to Candida BSI was calculated using three methods—propensity score matching, matching by inverse weighting of propensity score, and stratified analysis by quintile. The 90-day crude mortality was 42.4% (269 patients) for Candida BSI cases and 17.1% (1083 patients) for frequency-matched controls. Following propensity score-matching, the attributable risk difference for 90-day mortality was 28.4% with hazard ratio (HR) of 2.12 (95% confidence interval [CI], 1.98–2.25, P < .001). In the stratified analysis, the risk for mortality at 90 days was highest in patients in the lowest risk quintile to develop Candida BSI (hazard ratio [HR] 3.13 (95% CI, 2.33–4.19). Patients in this lowest risk quintile accounted for 81(61%) of the 130 untreated patients with Candida BSI. Sixty-nine percent of untreated patients (57/83) died versus 35% of (49/127) of treated patients (P < .001). Patients with Candida BSI continue to experience high mortality. Mortality attributable to Candida BSI was more pronounced in patients at lowest risk to develop Candida BSI. A higher proportion of these low-risk patients went untreated, experienced higher mortality, and should be the target of aggressive interventions to ensure timely, effective treatment.
- Open Access
- 8 May 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (5) , 369
Long-Term Mortality after Histoplasma Infection in People with HIV
Histoplasmosis is a common opportunistic infection in people with HIV (PWH); however, no study has looked at factors associated with the long-term mortality of histoplasmosis in PWH. We conducted a single-center retrospective study on the long-term mortality of PWH diagnosed with histoplasmosis between 2002 and 2017. Patients were categorized into three groups based on length of survival after diagnosis: early mortality (death < 90 days), late mortality (death ≥ 90 days), and long-term survivors. Patients diagnosed during or after 2008 were considered part of the modern antiretroviral therapy (ART) era. Insurance type (private vs. public) was a surrogate indicator of socioeconomic status. Out of 54 PWH infected with histoplasmosis, overall mortality was 37%; 14.8% early mortality and 22.2% late mortality. There was no statistically significant difference in survival based on the availability of modern ART (p = 0.60). Insurance status reached statistical significance with 38% of survivors having private insurance versus only 8% having private insurance in the late mortality group (p = 0.05). High mortality persists despite the advent of modern ART, implicating a contribution from social determinants of health, such as private insurance. Larger studies are needed to elucidate the role of these factors in the mortality of PWH.
- 8 May 2021
- Published by MDPI AG in Journal of Fungi
- Vol. 7 (5) , 369
Open AccessLong-Term Mortality after Histoplasma Infection in People with HIV
Histoplasmosis is a common opportunistic infection in people with HIV (PWH); however, no study has looked at factors associated with the long-term mortality of histoplasmosis in PWH. We conducted a single-center retrospective study on the long-term mortality of PWH diagnosed with histoplasmosis between 2002 and 2017. Patients were categorized into three groups based on length of survival after diagnosis: early mortality (death < 90 days), late mortality (death ≥ 90 days), and long-term survivors. Patients diagnosed during or after 2008 were considered part of the modern antiretroviral therapy (ART) era. Insurance type (private vs. public) was a surrogate indicator of socioeconomic status. Out of 54 PWH infected with histoplasmosis, overall mortality was 37%; 14.8% early mortality and 22.2% late mortality. There was no statistically significant difference in survival based on the availability of modern ART (p = 0.60). Insurance status reached statistical significance with 38% of survivors having private insurance versus only 8% having private insurance in the late mortality group (p = 0.05). High mortality persists despite the advent of modern ART, implicating a contribution from social determinants of health, such as private insurance. Larger studies are needed to elucidate the role of these factors in the mortality of PWH.